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Abstract
Background Undiagnosed obstructive sleep apnea
(OSA) is a highly prevalent breathing disorder. The pur-
pose of this study was to determine the effects of
preoperative screening and subsequent treatment for OSA
on the health of patients.
Methods We conducted a two-year follow-up study of
patients previously enrolled in a large prospective study in
which patients were given the STOP questionnaire for OSA
screening (n = 2,467). All patients who underwent a pol-
ysomnography were considered eligible (n = 211) and
were asked to complete a paper-based mailed question-
naire. The severity of OSA, comorbidities, and treatment
modalities and their effects were evaluated from the
returned questionnaire. Research ethics board approval
was obtained and returning the questionnaire implied
informed patient consent.
Results The response rate was 67%. One hundred
twenty-eight (82%) of the 156 patients who responded had
OSA established by polysomnography. Among these 128
patients with OSA, 88 (69%) were prescribed continuous
positive airway pressure (CPAP) therapy and 40 (31%)
were prescribed other (non-CPAP) treatment. Among those
88 patients receiving CPAP, 40 (45%) were compliant and
48 (55%) were non-compliant. The CPAP compliant
patients had a greater reduction in medication for
comorbidities than the CPAP non-compliant or the other
treatment group (38% vs 3% vs 0%, respectively;
P\0.001). A signiﬁcant improvement in snoring, sleep
quality, and daytime sleepiness was reported by CPAP
compliant users compared with CPAP non-compliant or
other treatment groups (P\0.001).
Conclusion The preoperative patients who were identi-
ﬁed to have OSA and were compliant with CPAP use may
have health beneﬁts in terms of improved snoring, sleep
quality, and daytime sleepiness. Timely diagnosis and
treatment compliance may reduce symptoms of OSA and
severity of associated comorbidities along with a reduction
in medications.
Re ´sume ´
Contexte Les apne ´es obstructives du sommeil non
diagnostique ´s (AOS) sont un trouble respiratoire
hautement pre ´valent. L’objectif de cette e ´tude e ´tait de
de ´terminer les effets d’un de ´pistage pre ´ope ´ratoire et du
traitement subse ´quent de l’AOS sur la sante ´ des patients.
Me ´thodes Nous avons mene ´ pendant deux ans une e ´tude
de suivi de patients ante ´rieurement inscrits dans une grande
e ´tude prospective au cours de laquelle le questionnaire
STOP avait e ´te ´ administre ´ pour le de ´pistage de l’AOS
(n = 2 467). Tous les patients ayant be ´ne ´ﬁcie ´ d’une
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il leur a e ´te ´ demande ´ de re ´pondre a ` un questionnaire
imprime ´ envoye ´ par courrier. La se ´ve ´rite ´ de l’AOS, les
comorbidite ´s et les modalite ´s the ´rapeutiques ainsi que leurs
effets ont e ´te ´ e ´value ´sa ` partir des questionnaires renvoye ´s.
L’accordducomite ´d’e ´thiquedelarechercheae ´te ´obtenuet
le retour du questionnaire impliquait le consentement
e ´claire ´du patient.
Re ´sultats Le taux de re ´ponse a e ´te ´ de 67 %. Cent
vingt-huit patients sur les 156 ayant re ´pondu (82 %)
avaient une OSA mise en e ´vidence par la polysomnographie.
Parmi ces 128 patients souffrant d’AOS, 88 (69 %) ont
rec ¸u une prescription de traitement par pression positive
continue des voies respiratoires (CPAP) et 40 (31 %) ont
eu un autre traitement (non-CPAP). Parmi les 88 patients
be ´ne ´ﬁciant d’une CPAP, 40 (45 %) e ´taient observants
et 48 (55 %) n’e ´taient pas observants. Les patients
observants de la CPAP pre ´sentaient une plus grande baisse
des traitements me ´dicamenteux pour comorbidite ´s par
rapport aux patients non observants ou que les patients de
l’autre groupe de traitement (respectivement, 38 %, 3 % et
0; P\0,001). Une ame ´lioration signiﬁcative du ronﬂement,
de la qualite ´ du sommeil et de la somnolence diurne a e ´te ´
signale ´e par les utilisateurs de CPAP observants compare ´s
aux utilisateurs de CPAP non observants ou aux patients des
autres groupes de traitement (P\0,001).
Conclusion Les patients qui avaient e ´te ´ identiﬁe ´se n
pre ´ope ´ratoire comme ayant une AOS et qui suivaient le
traitement par CPAP peuvent tirer des be ´ne ´ﬁces pour la
sante ´en termes de ronﬂements, de qualite ´du sommeil et de
somnolence diurne. Le diagnostic en temps opportun et
l’observance du traitement peuvent re ´duire les sympto ˆmes
d’AOS, la se ´ve ´rite ´des comorbidite ´s associe ´es et la prise de
me ´dicaments.
Introduction
Obstructive sleep apnea (OSA) is a disorder characterized
by intermittent closure of the upper airway during sleep,
resulting in sleep fragmentation and night-time hypoxemia.
Obstructive sleep apnea is the most prevalent breathing
disorder with an incidence of one in four men and one in
ten women.
1 In the general population, moderately severe
OSA is present in 11.4% of men and 4.7% of women.
2,3
Obstructive sleep apnea is associated with several comor-
bidities, including acute myocardial infarction, heart
failure, arrhythmias, refractory hypertension, cerebrovas-
cular diseases, and metabolic syndrome.
4-9
Anesthesiologists can play a crucial role in identifying
patients with OSA. The screening of patients in the pre-
operative clinic provides an opportunity to identify patients
at risk for OSA, thus directing them to the sleep physicians
for better patient outcome. A number of questionnaire-
based screening tools have been developed to screen OSA
patients, and there have been two recent reviews on the
topic of screening tests.
10,11 The STOP questionnaire was
developed and validated in our centre to screen surgical
patients for OSA, and it has been shown to be effective in
identifying patients at high risk for OSA.
12,13
Among the different treatment modalities available,
continuous positive airway pressure (CPAP) is the most
efﬁcient and the most widely used. Continuous positive
airway pressure is effective in reducing the nocturnal
events of OSA, and it may provide subjective beneﬁts, such
as improvement in daytime sleepiness, cognitive function,
and well-being.
14,15 Continuous positive airway pressure
has also been shown to decrease blood pressure in OSA
patients with hypertension, and it improves glucose control
in diabetic patients with severe OSA.
16,17 However, while
CPAP is highly effective in controlling symptoms of sleep
apnea, the device is cumbersome, and data show only
moderately satisfactory compliance.
18,19
The main objectives of the study were to determine the
health beneﬁts of diagnosing OSA in the surgical patients
in terms of improved snoring, sleep quality, daytime
sleepiness, subjective fatigue, and reduction of medication
to treat coexisting medical diseases.
Methods
Study design and patient population
This study was a two-year follow-up study of the patients
enrolled in a previous large prospective study designed to
develop a screening tool for OSA (STOP questionnaire).
Patients who had submitted to a polysomnography (PSG)
test were considered eligible and were asked to complete a
questionnaire related to their health condition.
Polysomnography is the ‘‘gold standard’’ diagnostic tool
for assessing sleep-disordered breathing. It requires an
overnight stay in a sleep laboratory with monitoring of
oxygen saturation, heart rate, sleep stage (via electroen-
cephalography), jaw muscle tone (via electromyography),
air ﬂow, nasal ﬂow, and chest and abdominal movement.
Respiratory parameters are measured to determine apneas
and hypopneas. Apnea has been deﬁned as a complete
cessation of airﬂow lasting C ten seconds, and hypopnea
has been deﬁned as a C 50% reduction in respiratory air-
ﬂow lasting longer than ten seconds and associated with an
arousal or oxygen desaturation by C 4%. The apnea-
hypopnea index (AHI), i.e., the number of obstructive
events per hour, is the measurement most commonly used
to quantify OSA: mild = 5-15; moderate = greater than
15-30; severe = greater than 30.
20
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123Among the patients enrolled in the original study
(n = 2,467), 416 consented to an overnight PSG, and 211
of those underwent the test due to ‘‘no shows’’. These 211
patients underwent various surgeries (neurosurgical,
orthopedic, spine, urologic, obstetric, general surgical
(except bariatric), and otorhinolaryngologic surgeries) at
Toronto Western and Mount Sinai Hospitals in Toronto.
The patients were then referred to sleep physicians at the
Sleep Clinic of Toronto Western Hospital within three
months of surgery. The sleep physicians subsequently
prescribed the different treatments depending on the diag-
nosis and followed up with the patients for treatment
compliance. In the present study, we conducted a follow-up
study of these 211 patients at two years.
Questionnaire development
In order to contact these patients and obtain information,
we devised a new questionnaire/template (for this study) to
administer to patients (Appendix). The questionnaire was
designed in three sections. The ﬁrst and second sections of
the questionnaire were derived from the standard questions
that were administered routinely to patients in our sleep
clinic on their ﬁrst and follow-up visits. The ﬁrst section
included a set of questions on diagnosis, treatment pre-
scription, and changes in OSA symptoms (e.g., snoring),
whereas the second section had questions on comorbidities.
The third section of the questionnaire included two vali-
dated sets of questions, i.e., the Epworth Sleepiness Scale
and the Fatigue Severity Scale.
The questions on CPAP compliance (ﬁrst section of
questionnaire) were focused on details regarding the
number of nights per week and hours per night of CPAP
use. Self-reported CPAP compliance was deﬁned as the use
of CPAP for[four hours per day for[ﬁve nights per
week.
21 Patients were asked to report any preexisting
medical conditions, such as hypertension, congestive heart
failure, arrhythmias, diabetes mellitus, asthma, gastro-
esophageal reﬂux disease, and/or depression. Patients were
also asked to specify any change or reduction in prescribed
medications, such as a reduction in antihypertensive drugs,
antiarrhythmic drugs, hypoglycemic drugs, antidepressant
drugs, and antacids. The reduction in medications was
deﬁned as a reduction in either the dosage or the total
number of prescribed medications.
The Fatigue Severity Scale measures the fatigue level
experienced by the patients.
22 Patients were asked ques-
tions to respond to nine different statements on a scale of
1-7 (1 = strongly disagree, and 7 = strongly agree). The
ﬁnal score is the mean of the nine items, and a higher score
indicates a higher fatigue level. The Fatigue Severity Scale
was measured before and two years after the treatment
prescription.
The Epworth Sleepiness Scale measures the general level
of daytime sleepiness as experienced by the patients.
23
Patients were asked to rate their chance to fall asleep during
different routine daytime situations on a scale of 0-3
(0 = little or no chance of dozing, and 3 = a high chance of
dozing. The ﬁnal score is the total score of eight items and
ranges from 0 to 24. A score C 10 is considered abnormal,
and a score[14 may suggest a more signiﬁcant degree of
daytime hypersomnolence. The Epworth Sleepiness Scale
was measured at two years after treatment prescription.
Questionnaire dissemination
The questionnaires speciﬁcally designed for the study
patients were mailed to all 211 patients with an accom-
panying cover letter. The cover letter provided information
about voluntary participation with no ﬁnancial remunera-
tion and instructions to patients not to identify themselves
on the questionnaire. The questionnaires were numbered,
however, to identify the respondents. The patients were
instructed to return the completed questionnaire in the pre-
stamped envelopes provided. If there was no response at
two weeks, a phone call was made to ensure completion of
the mailing process and to encourage the patients to return
the questionnaire with their responses. At four weeks, non-
respondents were requested to reply to the questionnaire
during a phone call. The returned questionnaires and sleep
study charts of the participants were reviewed by one of the
investigators (V.M.).
The study protocol was approved by the Hospital
Research Ethics Board (University Health Network, Tor-
onto, ON, Canada) (May 2010, # 10-0067-AE). The
requirement of a separate consent form was waived by the
Research Ethics Board, since returning the questionnaire
implied informed consent of the participant.
Statistics
The statistical analysis was performed using SPSS
 v17
(SPSS INC., Chicago, IL, USA) and MedCalc software
(MedCalc software, Mariakerke, Belgium). The data were
analyzed using descriptive statistics. The normality of data
distribution was tested using the D’Agostino-Pearson test.
Data are represented with number of patients, mean (SD) or
mean (95% conﬁdence interval of mean) as appropriate.
Continuous variables, such as age, body mass index (BMI),
neck circumference, Epworth Sleepiness Scale, and Fati-
gue Severity Scale were analyzed using the Student’s t test.
Use of AHI and CPAP were analyzed with the nonpara-
metric Mann-Whitney U test. Nominal variables, such as
sex and comorbidities were analyzed using the Chi square
test and Fischer’s exact test where appropriate. In all cases,
P\0.05 was considered statistically signiﬁcant.
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123Results
We mailed the questionnaires during June and July 2010.
One hundred ﬁfty-six of the 211 patients who underwent
PSG and were eligible for the study were ultimately
included in the ﬁnal analysis (Figure). Fifty-ﬁve patients
were excluded for various reasons: 24 patients could not be
contacted due to change of address and/or phone number,
28 patients declined to participate, and three patients were
deceased. Questionnaires were returned by 141 patients,
and 15 patients completed the questionnaire over the
phone.
As conﬁrmed by PSG two years prior to our contact, 128
(82%) of the 156 patients who responded to the
questionnaires had a diagnosis of OSA while 28 (18%) had
no diagnosis of OSA. The demographic data of the par-
ticipants are shown in Table 1. The OSA patients were
older with a higher BMI and a larger neck circumference
than the non-OSA patients. The AHI was also higher in
OSA patients vs non-OSA patients [20.9 (21.6) vs 1.8 (1.6),
respectively].
Among 128 patients with OSA, 88 (69%) were pre-
scribed CPAP therapy and 40 (31%) were prescribed non-
CPAP treatment modalities: advice on weight loss
(n = 11); improve sleep hygiene (n = 12); counselling for
follow-up and repeat PSG (n = 17). According to the
patients’ responses in the questionnaire regarding CPAP
compliance, 40 (45%) were compliant and 48 (55%) were
Consented for PSG after STOP 
questionnaire (n=416) 
Excluded (n=205) 
￿ No shows for PSG 
Patients who had PSG  
Enrolled in the present study (n=211) 
Patients who responded to questionnaires          
(n=156)
OSA present (n=128)  OSA absent (n= 28) 
CPAP (n=88)  Non-CPAP (n= 40) 
￿ Weight reduction (n=11) 
￿ Improve sleep hygiene (n=12) 
￿ Counselling (n=17) 
Compliant (n=40)  Non-compliant (n=48) 
￿ Never used (n=33) 
￿ Irregular use (n=15) 
Excluded (n=55) 
￿ Patients could not be contacted (n=24) 
￿ Declined to participate (n=28) 
￿ Deceased (n=3) 
Treatment for OSA
Figure Patient ﬂow chart
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123non-compliant with the prescribed CPAP treatment. The
compliant group used the CPAP on an average of six days
per week with a continuous use for more than six hours per
night. The difference in CPAP compliance between the
CPAP compliant and the CPAP non-compliant groups was
statistically signiﬁcant (Table 2). The patients receiving
non-CPAP treatment were younger, had a low BMI, and a
substantially lower AHI compared with the CPAP users.
Effects of treatment on comorbidities
Thirty-eight percent of the CPAP compliant patients
reported a reduction in medication vs 3% of the CPAP
non-compliant patients (P\0.001) (Table 3). Among the
38% of patients with a reduction in medication, 15% of
patients in the compliant group had a reduction in the total
number of prescribed medications. In the CPAP non-
compliant group, no patients had a reduction in the total
number of medications. Also, the patients receiving non-
CPAP treatment did not report any reduction in medication
for their coexisting medical conditions.
Effects of treatment on OSA symptoms
Improvement in snoring and sleep quality occurred in 36
(90%) and 35 (87%) of the CPAP compliant patients,
respectively, vs four (8%) of the CPAP non-compliant
patients (P\0.001). Improvement in tiredness was repor-
ted in 33 (82%) of CPAP compliant patients vs four (8%)
patients who were non-compliant and one (3%) patient who
received non-CPAP treatment modality (Table 4). The
major side effects of CPAP use reported by patients were
dry mouth (25%), dry nose (15%), and mask discomfort
(15%). Other complaints included occasional morning rhi-
norrhea, choking sensation, and ‘‘mask falling off’’.
Epworth Sleepiness Scale & Fatigue Severity Scale
The results of the Epworth Sleepiness Scale in the CPAP
compliant patients were signiﬁcantly lower than those in
the CPAP non-compliant patients (Table 4) and lower than
the results in patients receiving non-CPAP treatment. The
results of the Fatigue Severity Scale in the CPAP compliant
patients showed a signiﬁcant improvement in their sub-
jective feeling of fatigue post-treatment vs pre-treatment,
Table 1 Demographic data
OSA
(n = 128)
No OSA
(n = 28)
Sex (male/female) 72/56 9/19
Age (yr) 61 (12) 51 (15)
BMI (kgm
-2) 31.1 (7.0) 26.8 (5.4)
Neck circumference (cm) 39.2 (3.6) 34.8 (4.2)
Pre-existing conditions n (%)
Hypertension 64 (50) 11 (39.3)
CVD 10 (7.8) 4(14.3)
Diabetes 22 (17.2) 1 (3.6)
Asthma 11 (7.1) 2 (8.6)
GERD 22 (17.2) 6 (21.4)
Depression 31 (19.9) 5 (17.9)
AHI 20.9 (21.6) 1.8 (1.6)
Data are expressed as mean (standard deviation) or numbers (%).
OSA = obstructive sleep apnea; BMI = body mass index; CVD =
cardiovascular diseases, including angina, arrhythmia, and/or con-
gestive cardiac failure; GERD = gastroesophageal reﬂux disease;
AHI = apnea-hypopnea index
Table 2 Data on patients recommended with the different treatments
CPAP users Non-CPAP
treatment
(n = 40) Compliant
(n = 40)
Non-compliant
(n = 48)
Sex (male/female) 20/20 29/19 23/17
Age (yr) 63.2 (12) 63.7 (10) 54.9 (12)
BMI (kgm
-2) 33.2 (9) 30.5 (6) 29.7 (6)
Neck circumference (cm) 39.9 (5) 39.2 (4) 38.5 (4)
AHI 31.8 (28) 23.6 (18) 6.7 (4)
CPAP use
days/week 6.5 (0.9)* 0.5 (0.9) N/A
hours/night 6.3 (1.2)* 0.7 (1.1) N/A
Data expressed as number of patients or mean (standard deviation).
Other treatment = weight reduction and improving sleep hygiene.
*P\0.001 (CPAP compliant vs CPAP non-compliant). CPAP =
continuous positive airway pressure; BMI = body mass index; AHI =
apnea-hypopnea index; N/A = not applicable
Table 3 Percentages of patients reporting reduction in medication
after obstructive sleep apnea treatment
Comorbidities CPAP users Non-CPAP
treatment
(n = 40) (%)
P* value
Compliant
(n = 40)
(%)
Non-
compliant
(n = 48) (%)
Hypertension 28 5 0 0.05
Diabetes 12 0 0 1
CVD 12 0 0 1
Asthma 0 0 0 N/A
GERD 36 0 0 N/A
Depression 14 0 0 0.43
Overall
medication
reduction
38 3 0 \0.001
*Represents P value of the test difference between the CPAP com-
pliant and non-compliant groups. CPAP = continuous positive
airway pressure; CVD = cardiovascular diseases, including angina,
arrhythmia, and /or congestive cardiac failure; GERD = gastro-
esophageal reﬂux disease; N/A = not applicable
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123but there was no difference between CPAP compliant and
CPAP non-compliant patients (Table 4). The patients with
non-CPAP treatment modalities had improved Fatigue
Severity Scale results post-treatment vs pre-treatment,
however the difference was not statistically signiﬁcant.
Discussion
This study showed that[80% of CPAP compliant patients
showedimprovedsnoring,sleepquality,daytimesleepiness,
and fatigue, respectively. Thirty-eight percent of CPAP
compliantpatientshadself-reportedreductioninmedication
for coexisting diseases. The administration of the STOP
questionnaire as a screening tool for OSA was associated
with health beneﬁts for patients who were referred to the
sleep clinic and consequently experienced a reduction in the
severity of OSA-associated comorbid conditions.
We chose to follow the surgical patients screened and
diagnosed with OSA with a mailed questionnaire and a fol-
low-up phonecall. Wereceivedagoodresponse rateof67%
with this follow-up. This method was used successfully in
another study regarding long-term follow-up of OSA.
24
Compliance plays an important role in observing the
effects of the treatment. In two prospective studies evalu-
ating the factors of CPAP adherence and the rate of long-
term compliance, the rate of CPAP compliance ranged
from 28-84%.
25,26 In our study, the rate of CPAP compli-
ance was 45% at two years. Compared with the CPAP non-
compliant patients, the compliant patients had a higher
AHI at the start of this study with more severe symptoms of
obstructive sleep apnea. Their condition showed marked
improvement with CPAP use, a major reason for CPAP
compliance. On the other hand, patients with a non-CPAP
treatment prescription reported only minimum beneﬁts
from treatment, most likely due to mild OSA symptoms.
Non-compliance with CPAP has been a major issue in
treating the OSA patients with CPAP, and it can have a
signiﬁcant impact on the mortality associated with
untreated OSA. Marin et al. have shown that the patients
who are untreated or non-compliant with OSA treatment
tend to have high mortality.
27 Another study by Marshall
et al. showed that the hazard ratio of early death is 4.4-6.2
for untreated moderate to severe sleep apnea after con-
trolling for different covariates such as age, sex, BMI,
smoking status, and total cholesterol level.
28 The rate of
CPAP non-compliance in our study was 55%, and this non-
compliance to treatment partly explains the lack of beneﬁt
reported by our CPAP non-compliant group. Our result is
also consistent with other reports that 50% of patients
abandoned the use of CPAP within one year of ther-
apy.
29-32 The major reasons for CPAP non-compliance
were mild symptoms, cumbersome device, and side effects
like dry mouth, dry nose, and mask discomfort.
A strong association between OSA and hypertension has
been established by a number of studies.
33,34 A prospective
study identiﬁed that even minimally elevated AHI at
baseline was associated with 42% (95% conﬁdence inter-
val, 13 to 78) increased odds of developing hypertension
over a four-year follow-up period.
35 The effectiveness of
reducing blood pressure by treating OSA with CPAP has
been shown by several intervention studies.
36-39 In our
study, a larger percentage of CPAP compliant patients self-
reported a reduction in the dosage of anti-hypertensive
medication vs other groups of patients. Most importantly,
we found that the percentage of patients with a reduction of
medication for comorbidities was signiﬁcantly higher in
patients compliant to CPAP vs other groups of patients.
Excessive daytime sleepiness is a cardinal feature of the
OSA. A signiﬁcant, progressive increase in Epworth Sleep-
iness Scale score was shown to be associated with a sever-
ity of OSA.
40 Studies, including placebo or sham-CPAP
Table 4 Outcome measures in patients with obstructive sleep apnea
Outcome CPAP users Non-CPAP treatment
(n = 40)
Compliant (n = 40) Non-compliant (n = 48)
Improvement in snoring n (%) 36 (90)* 4 (8) N/A
Improvement in sleep quality n (%) 35 (87)* 4 (8) N/A
Improvement in tiredness n (%) 33 (82)*
 4 (8) 1 (3)
Weight loss n (%) 10 (25) 8 (17) 7 (18)
Physician visits 4.0 (3.1) (3.0 to 5.0) 4.0 (3.7) (3.0 to 5.1) 3.5 (2.6) (2.7 to 4.4)
Epworth Sleepiness Scale 5.3 (2.6) (4.4 to 6.1)*
 8.6 (5.1) (7.1 to 10) 7.4 (4.2) (6.1 to 8.7)
Fatigue Severity Scale
Pre-treatment 4.2 (1.4) (3.7 to 4.6)
§ 3.3 (1.7) (2.8 to 3.8) 3.2 (1.5) (2.7 to 3.7)
Post-treatment 2.7 (1.5) (2.2 to 3.2) 2.8 (1.6) (2.4 to 3.3) 2.7 (1.8) (2.1 to 3.2)
Data expressed as number (percent) or mean (standard deviation) (95% conﬁdence interval for mean) *P\0.001(CPAP compliant vs CPAP
non-compliant groups).
P\0.001, P\0.007 (CPAP compliant vs Non-CPAP treatment groups).
§P\0.001 (pre-treatment vs post-treatment
in CPAP compliant group). CPAP = continuous positive airway pressure; N/A = not applicable
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123controlled studies, have shown an improvement in daytime
sleepiness after treatment of OSA.
41,42 In context with
these studies, our patients who were treated and compliant
with CPAP reported an improvement in their daytime
sleepiness compared with other treatment groups.
Fatigue often coexists in patients with OSA as a con-
sequence of sleep fragmentation. In a recent prospective
observational study, subjective fatigue was identiﬁed as an
independent manifestation of sleep disorder along with
subjective sleepiness.
43 Before initiation of the treatment,
our patients with severe OSA symptoms reported higher
fatigue levels, which subsequently improved following
CPAP compliance.
From the economical perspective, OSA imposes signiﬁ-
cant health care expenditures on ﬁnite resources due to its
association with various comorbid diseases, particularly
hypertension, ischemic heart disease, and diabetes. Many
studies evaluating the economic implications of sleep dis-
ordershaveshownthatthehealthcareexpendituresforOSA
decline signiﬁcantly once the illness is properly treated with
weight reduction and/or CPAP.
44,45 Our study has shown
that surgical patients compliant with CPAP use beneﬁted
from OSA diagnosis and treatment with signiﬁcant
improvementindaytimesleepinessandfatigue.Thepatients
with non-CPAP treatment recommendations also reported
some improvement in their daytime somnolence and fatigue
levels; however, the results were not statistically signiﬁcant.
The CPAP compliant patients in our study had medication
reduction for comorbidities, which might reduce health care
expenditures as indicated by studies analyzing the economic
burden of OSA diagnosis and treatment.
46,47
There are certain limitations of the study. The results of
the study are based on a small sample size and sub-group
analysis of a large cohort study, which is a major limita-
tion. Also, the study is not a randomized clinical trial to
determine the beneﬁts of CPAP and other modalities of
treatment, but it is able to provide further evidence for the
beneﬁcial effects of CPAP by comparison of CPAP com-
pliant patients with a natural control group, the CPAP non-
compliant patients. However, it is difﬁcult to determine if
the beneﬁcial effects attributed to CPAP therapy were a
result of a selection bias. Also, the initial parts of ques-
tionnaires are non-validated and categorized as binary, as
opposed to a scale. We chose to use binary as we use this
approach routinely at our sleep clinics. Another possible
limitation is the risk of recall bias since patients had to rely
on their memory to answer the questionnaire. The self-
reported CPAP compliance may be signiﬁcantly higher
than that determined by the record stored in the CPAP
machine. Also, preoperative PSG testing, justiﬁed on the
basis of a STOP score suggestive of OSA, may not always
be possible before surgery depending on how soon the
patient is evaluated before the actual surgery. However,
there are still health beneﬁts from less daytime sleepiness,
less fatigue, and reduction of medications, even though the
referrals to a sleep physician may occur after surgery.
Although our study did not analyze the economic burden
on OSA patients, it does provide evidence of a possible
decline in health care expenditures based on the health
beneﬁts perceived by the patients.
In conclusion, this study suggests that those preoperative
patients who were identiﬁed as having OSA and who were
compliant with CPAP use may have health beneﬁts in
terms of improved snoring, better quality of sleep, and
lower levels of daytime sleepiness and fatigue. Timely
diagnosis and treatment compliance may reduce symptoms
of OSA and the severity of associated comorbidities with a
reduction in medication. Since the ﬁndings are based on a
small subgroup of CPAP compliant patients, a larger study
evaluating the clinically signiﬁcant outcomes needs to be
performed to further strengthen our suggested hypothesis.
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Appendix A follow-up questionnaire for screening
of obstructive sleep apnea
We would be grateful if you would answer the following
questions, which should take about 10 to 15 minutes to
complete. As mentioned in the information letter, we are
now trying to determine whether the diagnosis of sleep
apnea, made known by the screening in the preoperative
clinic, and its timely management did indeed provide
beneﬁcial effects. Furthermore, we want to determine
whether you had any change in symptoms, for example,
snoring, daytime sleepiness, fatigue, and tiredness. We also
would like to know how well you tolerate CPAP therapy if
it was prescribed for you, and whether you have any long-
term beneﬁts after diagnosis and treatment, such as a
reduction in blood pressure medications, fewer symptoms
of congestive heart failure, and better control of diabetes
mellitus, if you previously had any of those conditions.
We appreciate your time and participation in this study.
Your participation in this study is entirely voluntary. You
can choose not to answer any of the questions or you may
skip some questions if you wish.
Please answer the following questions to the best of your
knowledge:
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123o N s e Y ? e n o d y d u t s p e e l s e h t d a h u o y n e h w a e n p a p e e l s h t i w d e s o n g a i d u o y e r e W 1
o N s e Y ? t i r o f t n e m t a e r t y n a n e k a t u o y e v a h , 1 o t s e y f I 2
If no to question 1 or 2, please proceed to question 17, if yes to question 2, please proceed to question 3. 
? n e k a t u o y e v a h s e r u s a e m g n i w o l l o f e h t f o h c i h w , 2 n o i t s e u q o t s e y f I 3
￿ Prevent alcohol and caffeinated drinks before bedtime  Yes No 
￿ Refrain from sedative medication before bedtime  Yes No 
￿ Avoid sleeping in supine position  Yes No 
￿ Avoid big meals before bedtime  Yes No 
￿ Refrain from smoking before bedtime or midnight  Yes No 
￿ Refrain from eating at midnight  Yes No 
￿ Avoid sleep deprivation  Yes No 
￿ Sleep at least 7.5 hr per day  Yes No 
￿ Maintain regular sleep cycles  Yes No 
￿ Raise the head end of bed while sleeping  Yes No 
￿ Treat upper respiratory infections  Yes No   
o N s e Y ? a e n p a p e e l s r o f s n o i t a c i d e m c i f i c e p s y n a e k a t o t d e k s a u o y e r e W 4
￿ If yes, please list the drugs 
o N s e Y ? a e n p a p e e l s r o f d e m r o f r e p y r e g r u s y n a d a h u o y e v a H 5
￿ If yes, what kind of surgery did you have? 
6  Do you use CPAP or BiPAP devices? 
If yes, which device do you use: CPAP / BiPAP / APAP 
Yes No 
If no, go to question 15, If yes, answer the questions below 
7  What kind of mask do you use?      Nasal Pillow / Nasal Mask / Oral Mask / Oronasal Mask            
8  On average, how many days do you use your device in a week?      1, 2, 3, 4, 5, 6, 7 
On average, how many hours per night do you use your device?     1, 2, 3, 4, 5, 6, 7, 8, 9, 10 
9  How has your sleep changed?                           Better / No change / Worse  
10  How has your snoring changed?                         Better / No change / Worse 
11  o N s e Y ? r e d r o s i d d e t a l e r p e e l s r e h t o y n a e v a h u o y o D
￿ If Yes, please specify                                 ________________ 
12  How long did it take you to get used to your device?    ____________days/weeks 
13  Do you still use your device?  Yes No   
￿ If yes, is there a change in settings of the device over time?  Yes No   
     If yes, what is the change in the settings?        
￿ If no, why did you stop using it?   
14  o N s e Y ? e c i v e d P A P i B / P A P C f o e s u e h t h t i w s t c e f f e e d i s y n a e v a h u o y o D
￿ If yes, what are they 
o N s e Y ? d e v i e c e r u o y t n e m t a e r t e h t h t i w e l b a t r o f m o c l e e f u o y o D 5 1
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12316  Is there any specific problem you had with the treatment?      __________________ 
o N s e Y ? e r u s s e r p d o o l b h g i h r o f d e t a e r t u o y e r a r o e r u s s e r p d o o l b h g i h e v a h u o y o D 7 1
￿ If yes, is there any change in your medications for high blood pressure after receiving the 
treatment for sleep apnea? 
Yes No 
￿ If yes, please specify.  
18  Do you have diabetes?  Yes No 
￿ If yes, is there any change in the medications after OSA treatment?  Yes No 
￿ If yes, please specify 
19  Do you have cardiovascular disease? 
￿ Angina/Myocardial ischemia/arrhythmias/congestive cardiac failure 
￿ If yes, is there any change in the medications after OSA treatment?  Yes No 
￿ If yes, please specify 
20  Do you have asthma?  Yes No 
￿ If yes, is there any change in the medications after OSA treatment?  Yes No 
￿ If yes, please specify 
o N s e Y ? n o i s s e r p e d m o r f r e f f u s u o y k n i h t u o y o D 1 2
￿ If yes, is there any change in the medications after OSA treatment?  Yes No 
￿ If yes, please specify. 
o N s e Y ? e s a e s i d x u l f e r l a e g a h p o s e o r t s a g e v a h u o y o D 2 2
￿ If yes, is there any change in the medications after OSA treatment?  Yes No 
￿ If yes, please specify.  
23    Have you noticed any change in the severity of tiredness compared with previously?                           Yes       No 
If yes, is it better or worse?                       Better / Worse 
24  How has your body weight been after the initial treatment?  
            Increased             decreased               not changed 
   If there has been a weight change, by how many pounds has it changed? 
25  Do you sleep on your side?  Yes No 
26  Do you sleep with the bed raised higher than previously?   Yes  No 
27  Did you feel sleepy while you were driving?   Yes  No 
  Is there any change in your sleepiness while driving after receiving treatment?  Getting better / becoming 
worse? 
28  How many times have you visited the physician in the last year either directly or indirectly related to sleep 
apnea?   
29  Has there been a change in frequency of medical visits?  Yes  No 
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123Situation Chance of dozing 
(0 to 3)
Sitting and reading  0 1 2 3 
Watching television  0 1 2 3 
3 2 1 0 g n i t e e m r o r e t a e h t a , e l p m a x e r o f - - e c a l p c i l b u p a n i e v i t c a n i g n i t t i S
3 2 1 0 k a e r b a t u o h t i w r u o h n a r o f r a c a n i r e g n e s s a p a s A
3 2 1 0 n o o n r e t f a e h t n i t s e r o t n w o d g n i y L
3 2 1 0 e n o e m o s o t g n i k l a t d n a g n i t t i S
3 2 1 0 ) l o h o c l a o n d a h e v ' u o y n e h w ( h c n u l r e t f a y l t e i u q g n i t t i S
3 2 1 0 c i f f a r t n i d e p p o t s e l i h w r a c a n I
Total Score:
Total Score: 
        0-10   Normal range     10-12   Borderline       12-24   Abnormal 
30. Epworth sleepiness scale 
The Epworth Sleepiness Scale (ESS) will help you measure your general level of daytime sleepiness. You are to rate the chance that you 
would doze off or fall asleep during different routine daytime situations. Each item is rated from 0 to 3, with 0 meaning you would never 
doze or fall asleep in a given situation, and 3 meaning that there is a very high chance that you would doze or fall asleep in that situation. 
How likely are you to doze off or fall asleep in the following situations, in contrast to just feeling tired? Even if you haven't done some of 
these activities recently, think about how they would have affected you.
Use this scale to choose the most appropriate number for each situation: 
0 = would never doze 
1 = slight chance of dozing 
2 = moderate chance of dozing 
3 = high chance of dozing 
It is important that you circle a number (0 to 3) on each of the questions. 
31. Fatigue severity scale
Respond to each statement on a scale of 1 to 7, with 1 indicating “Strongly Disagree” and 7 indicating “Strongly Agree.”
Statements:
1. My motivation is lower when I am fatigued.  ______________
2. Exercise brings on my fatigue.  ______________
3. I am easily fatigued.  ______________
4. Fatigue interferes with my physical functioning.  ______________
5. Fatigue causes frequent problems for me.  ______________
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